1/10th dose vaccine, whereas response rates for T cells were similar
for the 1/10th and full dose.
-- 2nd MVA vaccination positively increased the number of CD8 T cell
responders and antibody responders.
-- Excellent results led to authorization to start two new trials with
GeoVax HIV/AIDS vaccines which began in June 2007.
-- In September, GeoVax responded to the announcement by Merck & Co., Inc.
that Merck's candidate AIDS vaccine failed to provide protection in a
human study designed to test for efficacy. In this Merck trial
involving high risk volunteers, an equal number of people received
either placebo or AIDS vaccine. The independent Data Safety Monitoring
Board recommended that the trial be stopped because it was not reaching
its efficacy endpoints. GeoVax responded to the discontinuance of
Merck's trial by pointing out significant differences between the
GeoVax vaccine technology and the technology used in the Merck trial.
GeoVax AIDS vaccines advancing in human trials represent a
significantly different vaccine approach, vaccine composition and
results to date than the Merck vaccine.
-- Prototypes for the GeoVax vaccines were selected from a series of
trials in non-human primates for their ability to protect against the
development of AIDS when vaccinated individuals were administered an
AIDS causing virus. At each major step along the development pathway,
GeoVax vaccines providing the best protection against AIDS were moved
-- GeoVax AIDS vaccines demonstrated excellent protective results in
non-human primate models, much better protective results than
reported for Merck's vaccine in similar models. GeoVax AIDS vacci
|SOURCE GeoVax Labs, Inc.|
Copyright©2008 PR Newswire.
All rights reserved